Erlotinib
- TRADE NAME: Tarceva (OSI)
- INDICATIONS: Non-small cell lung cancer, pancreatic cancer (with gemcitabine)
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Biologic, Epidermal growth factor receptor (EGFR) inhibitor / antagonist, Tyrosine kinase inhibitor
- HALF-LIFE: ~36 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atazanavir, Capecitabine, Carbamazepine, Ciprofloxacin, Clarithromycin, Diclofenac, Itraconazole, Ketoconazole, Meloxicam, Nefazodone, Nelfinavir, Omeprazole, Pantoprazole, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Troleandomycin, Voriconazole, Warfarin
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTIC.
RENAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of erlotinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/29/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
